Momegalen (Mometasone Furoate)

Mometasone furoate is a potent glucocorticoid that binds to glucocorticoid receptors in nasal epithelial cells. This binding alters gene transcription, suppressing the production of inflammatory mediators like cytokines and chemokines, while enhancing anti‑inflammatory proteins. The result is decreased swelling, mucus, and immune cell infiltration in the nasal lining.

The specific dosing regimen for Momegalen is determined by the prescribing healthcare professional based on the patient’s age, severity of symptoms, and clinical response. Patients should follow the prescriber’s instructions and the product’s label for the number of sprays per nostril and frequency of use.

Safety data for mometasone furoate nasal spray in pregnancy and lactation are limited. The prescriber should weigh the potential benefits against any possible risks to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss use with their healthcare provider.

To request Momegalen, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Momegalen’s active ingredient, mometasone furoate, is a high‑potency corticosteroid with minimal systemic absorption compared with some older nasal steroids such as beclomethasone. This profile offers effective symptom control with a lower risk of systemic side effects, making it a preferred option for many clinicians treating moderate to severe nasal inflammation.

Store Momegalen at ambient temperature, below 25 °C. Keep the spray in its original packaging, protect it from moisture, excessive heat, and direct sunlight. Do not freeze the product, and ensure the cap is tightly closed when not in use.

Momegalen is administered as a nasal spray. The patient should gently blow the nose, tilt the head slightly forward, insert the nozzle into one nostril, and press the actuator while breathing in gently through the nose. The recommended number of sprays per nostril is determined by the prescriber.

Serious but rare risks include nasal septal perforation, cataracts or glaucoma with prolonged use, adrenal suppression, and opportunistic fungal infections of the nasal mucosa. Patients should report persistent nosebleeds, visual changes, severe headache, or signs of systemic steroid effects to their healthcare provider promptly.

Momegalen should be avoided in individuals with known hypersensitivity to mometasone furoate or any component of the formulation. It is also contraindicated in patients with active untreated nasal infections, recent nasal surgery or trauma, and in those who are already using multiple intranasal corticosteroids without medical supervision.